Sanford Health & TruGenomix Announce Partnership To Commercialize Genomic Test For PTSD

Sanford Health, the large provider organization for rural health care, announced an $800,000 investment in TruGenomix, a veteran-owned precision behavioral health company. As part of the strategic partnership, Sanford Health will support TruGenomix by providing its state-of-the-art lab and research capabilities to validate a first-to-market patented blood test for post-traumatic stress disorder (PTSD).

Sanford Imagenetics will sequence 2,000 samples using TruGen-1, a laboratory-developed blood test (LDT), which is based on decades of research culminating in a patent for gene expression biomarker profiles that identify an individual's risk of . . .